NDAQ:BTAI - Post Discussion
Post by
whytestocks on Sep 19, 2024 7:32pm
BioXcel Therapeutics Announces Clinical Prioritization and U
Breaking News: $BTAI BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationRecently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA for TRANQUILITY In-Care pivotal Phase 3 trial for agitation associated with Alzheimer’s dementia Company to maintain IG...
BTAI - BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
Be the first to comment on this post